Proteome Analysis of Gelatin-Bound Urinary Proteins from Patients with Bladder Cancers

Saito, Minoru; Kimoto, Masafumi; Araki, Takeshi; Shimada, Yukie; Fujii, Ryoji; Oofusa, Ken; Hide, Michihiro; Usui, Tsuguru; Yoshizato, Katsutoshi

doi:10.1016/j.eururo.2005.04.028

Cited by 53 publications

(34 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urine proteome analysis toward the discovery of bladder cancer biomarkers has been clearly demonstrated by using 2-DE/MS or SELID-TOF-MS approaches [283][284][285][286][287][288][289][290][291]. Some putative markers discovered for bladder cancer included urinary psoriasin, calreticulin (CRT), gamma-synuclein (SNCG), catechol-omethyltransferase (COMT), orosomucoid, zinc-alpha-2-glycoprotein, matrix metalloproteinase-2 (MMP-2), MMP-9, fibronectin, and their fragments [284][285][286][287][288]. As a combination, CRT, SNCG, and COMT exhibited an overall sensitivity of 76.8% and specificity of 77.4%.…”

Section: Application To Human Disease Detectionmentioning

confidence: 99%

Human body fluid proteome analysis

2006

View full text Add to dashboard Cite

The focus of this article is to review the recent advances in proteome analysis of human body fluids, including plasma/serum, urine, cerebrospinal fluid, saliva, bronchoalveolar lavage fluid, synovial fluid, nipple aspirate fluid, tear fluid, and amniotic fluid, as well as its applications to human disease biomarker discovery. We aim to summarize the proteomics technologies currently used for global identification and quantification of body fluid proteins, and elaborate the putative biomarkers discovered for a variety of human diseases through human body fluid proteome (HBFP) analysis. Some critical concerns and perspectives in this emerging field are also discussed. With the advances made in proteomics technologies, the impact of HBFP analysis in the search for clinically relevant disease biomarkers would be realized in the future.

show abstract

Section: Application To Human Disease Detectionmentioning

confidence: 99%

Human body fluid proteome analysis

2006

View full text Add to dashboard Cite

show abstract

“…Urinary proteomics has great potential in biomarker discovery of kidney diseases and non-kidney diseases such as coronary artery atherosclerosis (von Zur Muhlen et al, 2009), prostate cancer (Theodorescu et al, 2008), and urinary bladder cancer (Saito et al, 2005). To date, more and more laboratories have engaged in urinary proteomic research and a great number of satisfying advances have been achieved, among which biomarker discovery in kidney diseases discussed above is one of the most exciting and significant ones.…”

Section: Resultsmentioning

confidence: 99%

Urinary proteomics as a novel tool for biomarker discovery in kidney diseases

Chen

2010

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Urine has become one of the most attractive biofluids in clinical proteomics, for its procurement is easy and noninvasive and it contains sufficient proteins and peptides. Urinary proteomics has thus rapidly developed and has been extensively applied to biomarker discovery in clinical diseases, especially kidney diseases. In this review, we discuss two important aspects of urinary proteomics in detail, namely, sample preparation and proteomic technologies. In addition, data mining in urinary proteomics is also briefly introduced. At last, we present several successful examples on the application of urinary proteomics for biomarker discovery in kidney diseases, including diabetic nephropathy, IgA nephropathy, lupus nephritis, renal Fanconi syndrome, acute kidney injury, and renal allograft rejection.

show abstract

“…Recent studies identified potential urinary biomarkers of TCC by 2-DE [190]. Another approach analysing changes in PTMs of urinary proteins in TCC patients concluded that these changes may provide practical information for the identification of patients with TCC at early stage [191]. SELDI-TOF has been applied in this type of cancer [192,193].…”

Section: Urinementioning

confidence: 99%

A better understanding of molecular mechanisms underlying human disease

Bermúdez-Crespo

López

2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

This review summarises and discusses the degree to which proteomics is contributing to medical care, providing examples and signspots for future directions. Why do genomic approaches provide a limited view of gene expression? Because of the multifactorial nature of many diseases, proteomics enables us to understand the molecular basis of disease, not only at the organism, whole‐cell or tissue levels, but also in subcellular structures, protein complexes and biological fluids. The application of proteomics in medicine is expected to have a major impact by providing an integrated view of individual disease processes. This review describes several proteomic platforms and examines the role of proteomics as a tool for clinical biomarker discovery, the identification of prognostic and earlier diagnostic markers, their use in monitoring the effects of drug treatments and eventually find more efficient and safer therapeutics for a wide range of pathologies.

show abstract

Proteome Analysis of Gelatin-Bound Urinary Proteins from Patients with Bladder Cancers

Cited by 53 publications

References 13 publications

Human body fluid proteome analysis

Human body fluid proteome analysis

Urinary proteomics as a novel tool for biomarker discovery in kidney diseases

A better understanding of molecular mechanisms underlying human disease

Contact Info

Product

Resources

About